Wardley, Andrew M <br/><br/>
Randomized phase II trial of first-line trastuzumab plus docetaxel and capecitabine compared with trastuzumab plus docetaxel in HER2-positive metastatic breast cancer.  [electronic resource] 

 -  Journal of clinical oncology : official journal of the American Society of Clinical Oncology  Feb 2010 
 - 976-83 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1527-7755 
<br/><br/><label>Standard No.: </label>10.1200/JCO.2008.21.6531  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Aged, 80 and over<br/>Antibodies, Monoclonal--administration & dosage<br/>Antibodies, Monoclonal, Humanized<br/>Antineoplastic Combined Chemotherapy Protocols--therapeutic use<br/>Bone Neoplasms--drug therapy<br/>Breast Neoplasms--drug therapy<br/>Capecitabine<br/>Deoxycytidine--administration & dosage<br/>Docetaxel<br/>Feasibility Studies<br/>Female<br/>Fluorouracil--administration & dosage<br/>Humans<br/>In Situ Hybridization, Fluorescence<br/>International Agencies<br/>Liver Neoplasms--drug therapy<br/>Middle Aged<br/>Neoplasm Staging<br/>Prognosis<br/>Receptor, ErbB-2--genetics<br/>Soft Tissue Neoplasms--drug therapy<br/>Survival Rate<br/>Taxoids--administration & dosage<br/>Trastuzumab<br/>Treatment Outcome<br/>Young Adult